NEWTON, Mass.--(BUSINESS WIRE)--Pro-Pharmaceuticals, Inc. (AMEX: PRW), a bio-pharmaceutical company developing proprietary polysaccharide-based therapeutic compounds to treat cancer, has submitted supporting clinical and manufacturing data to the U.S. Food and Drug Administration (FDA) for a New Drug Application (NDA) registration of DAVANAT®, a new chemical entity, for the treatment of advanced colorectal cancer. The Company has requested a meeting with the FDA to review the PK study needed to complete the request for the NDA.
